Jump to content


Hang onto your hat: Sclero Forums Upgrade May 14-21, 2017!! The Forums will be offline for up to 4 days, and then will return with an entirely new look and feel.


Pulmonary Fibrosis In Systemic Sclerosis And Dermatomyositis Demonstrates Marked Improvement After Administration Of Mycophenolate Mofetil


  • Please log in to reply
No replies to this topic

#1 Guest_Jude the Grouch_*

Guest_Jude the Grouch_*
  • Guests

Posted 30 August 2007 - 08:44 AM

Pulmonary Fibrosis In Systemic Sclerosis (SSc) And Dermatomyositis (DM) Demonstrates Marked Improvement After Administration Of Mycophenolate Mofetil (MMF/Cellcept). MMF's immunomodulatory and inhibitory effects on fibroblasts and other non-immune cells and a well established low side effect profile with high tolerance make MMF a potential alternative to cyclophosphamide in the treatment of SSc or DM related interstitial lung disease. L. A. Saketkoo THU0315 EULAR 2007. (Also see: Pulmonary Fibrosis and Dermatomyositis)